Publication: Forbes
The House Energy and Commerce Health Subcommittee held a hearing on “Opportunities to Improve the 340B Drug Pricing Program,” and Dr. Debra Patt, medical oncologist with Texas Oncology—Austin Central, was among the witnesses who testified. Dr. Patt states that, because of the lack of transparency, oversight, and accountability, we can observe tremendous variability across the country in the philanthropic commitment of 340B hospitals in using additional revenue to enhance care for vulnerable patient populations.
Read the full story at Forbes.